R-Tech Ueno is pleased to announce the start of the patient enrollment of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the treatment of retinitis pigmentosa.
Author: The Medical News
Eye health can be possible through nutrition and supplements, say experts
Eating healthy can affect more than what the scale says. According to experts at the University of Alabama at Birmingham, it is possible to aid eye health through nutrition and supplements.
Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease
WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into…
New procedure to treat pseudotumor cerebri
A team of interventional neuroradiologists and neurosurgeons at Johns Hopkins reports wide success with a new procedure to treat pseudotumor cerebri, a rare but potentially blinding condition marked by excessive pressure inside the skull, caused by a d…
Researchers work on stem cell treatments to halt vision loss caused by diabetic retinopathy
Researchers at the Eugene and Marilyn Glick Eye Institute and the Indiana Center for Vascular Biology at Indiana University School of Medicine are on the cusp of perfecting stem cell treatments that would halt – and potentially reverse – vision loss ca…
Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat
Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in i…
Peer support groups help combat epilepsy-related stigma
Peer support groups show promise for combating the debilitating stigma that surrounds epilepsy in much of the developing world, according to a new study led by a Michigan State University medical student.
Lack of very long chain fatty acids does not cause blindness in children with Stargardt type 3
Vision scientists long have thought that lack of very long chain fatty acids in photoreceptor cells caused blindness in children with Stargardt type 3 retinal degeneration, an incurable eye disease. But researchers at the University of Utah’s John A. M…
Reduced visual sensitivity seen with use of multifocal intraocular lenses
Recent study findings indicate that eyes with multifocal intraocular lenses implanted during cataract surgery may develop reduced visual sensitivity.
Antibiotic prophylaxis after IVT may be harmful
Researchers are warning against routine antibiotic prophylaxis with intravitreal injection after finding that the practice can increase the antibiotic resistance of ocular surface flora.
Study shows community-based HIV-prevention efforts increase testing rates, reduce HIV incidence
In Africa and Thailand, communities that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study presented this week at the Conference on Retroviruses and Opportunistic Infec…
Subclinical inflammation predicts macular disease
Levels of high-sensitivity C-reactive protein predict the risk for age-related macular degeneration and diabetic macular edema, show results of two independent studies published in JAMA Ophthalmology.
Global eye health company, Bausch + Lomb, names Robert Bertolini as president and chief financial officer
Bausch + Lomb, the global eye health company, has named Robert Bertolini as president and chief financial officer effective immediately. In this capacity, he will oversee the company’s Finance, Information Technology and Global Quality and Operations (…
Ampio Pharmaceuticals starts Optina clinical trial
Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.
Vision CRC develops retinal camera for detection of blinding eye disease and general health disorders
The most advanced technology for use in real-time detection and assessment of common blinding eye disease and general health disorders will soon be available to the world with stimulus funding provided for development by the Australian Government’s CRC…
Clearview announces arrival of Catalys Precision Laser System in Southern CA
Clearview Eye & Laser Medical Center announces the arrival of the world’s most sophisticated laser cataract surgery system in Southern CA.
Study finds new mutation in UBIAD1 gene that causes Schnyder corneal dystrophy
Research conducted by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology at LSU Health Sciences Center New Orleans, and colleagues has discovered a new mutation in a gene that causes Schnyder corneal dystrophy (SCD.)
International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.
Tips to help reduce dry eyes
Some of the last days of winter can be among the worst for your eyes. Winter may be slowly giving way to spring, but the remaining cold days of the season can cause plenty of trouble for the eyes—trouble that is largely avoidable, says a Vanderbilt Eye Institute ophthalmologist.
Sucampo launches RESCULA Eye Drops in the U.S.
Sucampo Pharmaceuticals, Inc. announced that RESCULA Eye Drops had been launched in the U.S. market.